Pulse Edition 20
The AI & Analytics Pulse
Welcome to the Twentieth Edition of Nu-Pie Pulse
In this edition of Nu-Pie Pulse:
Is the ROI on networking events bleeding out? Do you have 80+ business cards with close to Zero follow-ups? Do you spend 2 weeks just to land up sending a cold email? Nu-Pie felt your pain and has built a solution. With “Network Pro” you just scan, connect, message and book your first meeting while you're still shaking hands.
AstraZeneca just hired an AI analyst that never sleeps, never misses a trial, and never asks for a raise. The Owkin deal didn't just automate competitive intelligence. It rewired how pharma strategy gets made. Every boardroom is next.
$20 billion by 2032. 30.5% growth. Every single year. Pharma stopped shopping for AI tools. It started building the rails AI runs on. The companies that own the data layer will own the decade.
Isomorphic Labs raises $2.1 billion. Sovereign funds from three governments. Pharma's AI drug discovery just became national infrastructure and this isn't a startup bet anymore. It's a geopolitical arms race and the starting gun just fired.
Nu-Pie in Motion
You left the event with 80business cards
Two weeks later, you've followed up with none.
Most professionals walk out of every conference with a stack of contacts and the best intentions. But then…….
The Problem Worth Solving
We network at events, meet incredible potential clients, and leave inspired. Yet, a week or two later, it often feels like it was all a waste of time.
Why? Because visiting cards stay just cards. The exciting conversations end right where they began, and promised meetings never materialize.
The heaviest lifting happens after the event. The "great meeting you" message, the “context sharing” email, and the calendar invite and meeting scheduling require flawless, timely execution. When post-event inertia sets in, momentum is lost.
The connect was there, but the time spent trying to convert that spark into a meeting should have been better spent building the relationship.
The Solution: Network Pro
Network Pro is an AI-powered networking tool built to eliminate this operational frustration in four simple steps:
Scan: Instantly capture business cards via your phone camera.
Contextualize: Automatically generate personalized follow-up messages tailored to the specific event.
Automate: Initiate a seamless WhatsApp conversation.
Schedule: Handle calendar blocking and share meeting links instantly.
What used to be a two-week administrative bottleneck now takes 60 seconds completed while you are still shaking hands on the event floor. It runs inside the tools professionals already use, meaning zero complex onboarding and no external dependencies.
Explore the tool at: nu-pie.ai/products/networkpro
What Business leaders should watch
This was an incredibly hard problem to solve just three years ago. Today, it isn't. We built and deployed this tool in just under a week without a massive budget or long development cycles. We used a genuine problem and the AI tools available to businesses today.
Don't just watch the AI revolution. If you want to accelerate your own operational workflows or build agile tools like this for your organization, let's talk. We’ve done it, and we can help you build it too.
Industry Signals
The Industry Rewrite Has Started
AI isn’t assisting pharma anymore, it’s rebuilding it.
AstraZeneca × Owkin: AI Agents Are Now Running Pharma's Competitive Intelligence
Pharma's strategy rooms just got an AI analyst that never sleeps.
What's Happened:
Owkin announced a three-year licensing agreement with AstraZeneca to build and deploy biopharma AI agents powered by its K Pro, AI Scientist platform. Under the deal, Owkin will lead end-to-end development of AI agents integrated directly into AstraZeneca's IT infrastructure and decision workflows. The competitive intelligence agent is designed to analyze clinical trial activity for specific targets and compounds, tracking recruitment trends, potential outcomes, and patent filings, all to support strategy, clinical trial planning, and internal decision-making.
Why It Matters:
Traditional workflows often require teams of analysts, researchers, and consultants to manually synthesize fragmented information from scientific papers, trial databases, patents, conference presentations, and internal datasets. Replacing that with an always-on AI agent embedded directly inside AstraZeneca's systems isn't just a productivity gain it's a structural change in how pharma strategy gets made. Decisions that took weeks now take hours, and the companies that move fastest on pipeline intelligence will increasingly win the deals and licensing races that shape drug portfolios.
"At Owkin, we believe the future of the pharmaceutical industry is agentic”.
Thomas Clozel, CEO & Co-Founder, Owkin
Nu-Pie's Take:
This round changes the competitive math for every AI biotech playing at smaller scale. With $2.6 billion in total capital and sovereign fund backing, Isomorphic can out-hire, out-compute, and out-partner almost any rival. The real question isn't whether IsoDDE works it's whether Isomorphic can move fast enough from model to molecule to clinical milestone before the next generation of competitors close the gap. Watch for a first-in-human dosing announcement before year-end.
Source: FierceBiotech | Benzinga | MobiHealthNews
AI Drug Discovery Infrastructure Market to Hit $20 Billion by 2032 The Build Phase Has Begun
Pharma spent years talking about AI. The numbers say it's finally building with it.
What's Happened:
The global AI Drug Discovery Infrastructure Market was valued at $3.10 billion in 2025 and is projected to reach $19.98 billion by 2032, expanding at a CAGR of 30.5% during 2026–2032. This week's market report lands as the sector sees its largest-ever funding rounds with Isomorphic Labs' $2.1 billion raise and AstraZeneca's K Pro deal confirming that pharma is no longer piloting AI, it's building permanent infrastructure around it. AI partnerships and Pharma 4.0 technologies are cutting molecule design from months to weeks and reducing target identification phases by 28%, while smart factories are slashing production cycle times by up to 40% through real-time analytics.
Why It Matters:
A 30.5% annual growth rate in AI infrastructure not software tools, not pilots, but foundational compute and data platforms reflect a sector-wide transition. Pharma companies aren't just buying AI subscriptions anymore; they are investing in the rails that AI runs on: proprietary data networks, biological foundation models, agentic operating layers embedded into enterprise systems. The companies that own this infrastructure will hold the structural advantage in drug development for the next decade.
"If 2025 was the year of breakthrough research, 2026 will become the year of deployment." Jack Dent, Co-Founder, Chai Discovery
Nu-Pie's Take:
A $20 billion market by 2032 sounds impressive. What's more significant is the shape of the growth it's infrastructure, not application. That means the value is concentrating at the data and compute layer, not the model layer. Whoever controls the proprietary biological training data and the agentic orchestration layer will extract disproportionate value from this market. This is why Roche bought PathAI, why AWS built Bio Discovery, and why Owkin just signed AZ. The infrastructure arms race is the real story of pharma AI in 2026.
Source: Pharmaceutical Commerce | OpenPR
Isomorphic Labs Raises $2.1 Billion to Scale its AI Drug Design Engine
DeepMind's drug discovery spinout just became one of the most funded AI biotechs on the planet.
What's Happened:
Isomorphic Labs, an AI-first drug design and development company, announced it has raised $2.1 billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The new capital will be used for the continued development and deployment of IsoDDE Isomorphic Labs' AI Drug Design Engine accelerating and expanding its pipeline of therapeutic programs towards the clinic. Isomorphic already maintains strategic partnerships with Novartis, Lilly, and Johnson & Johnson.
Why It Matters:
The $2.1 billion Series B is one of the largest private rounds ever for AI drug discovery, bringing Isomorphic's total capital base to approximately $2.6 billion. The participation of sovereign wealth funds from the UK, Abu Dhabi, and Singapore signals this is no longer a tech bet, it's a geopolitical one. Governments are now backing AI drug discovery as strategic national infrastructure, not just venture upside.
“Now that we have shown that our approach works in principle, our focus is on scaling the technology to its full potential”.
Sir Demis Hassabis, CEO, Isomorphic Labs
Nu-Pie's Take:
This round changes the competitive math for every AI biotech playing at smaller scale. With $2.6 billion in total capital and sovereign fund backing, Isomorphic can out-hire, out-compute, and out-partner almost any rival. The real question isn't whether IsoDDE works it's whether Isomorphic can move fast enough from model to molecule to clinical milestone before the next generation of competitors close the gap. Watch for a first-in-human dosing announcement before year-end.
Source: PRNewswire | BioSpace | BioPharm International
Enjoyed The Content?
Why Subscribe to Nu-Pie Pulse?
Each edition, we deliver the best of analytics, AI, and human brilliance in a crisp, curated edition.
Let’s decode data. Let’s build what’s next. Let’s do it - together.
- Team Nu-Pie
Think Analytics. Think Nu-Pie.
Let’s stay in touch!